Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $65.64.

Several brokerages recently commented on IMCR. Morgan Stanley restated an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Friday. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $71.00 price target on shares of Immunocore in a research report on Thursday.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore in the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the last quarter. NEOS Investment Management LLC lifted its holdings in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares during the period. Tema Etfs LLC bought a new stake in shares of Immunocore during the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC increased its stake in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after acquiring an additional 3,238 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Trading Down 0.7 %

NASDAQ:IMCR opened at $29.37 on Monday. The company has a market cap of $1.47 billion, a P/E ratio of -30.92 and a beta of 0.77. Immunocore has a twelve month low of $27.69 and a twelve month high of $72.05. The business has a 50 day moving average price of $30.08 and a two-hundred day moving average price of $31.89. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.